Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
LONG COVID: PAZIENTE ADULTO TRATTATO CON SUCCESSO GRAZIE A TERAPIA CON ANTICORPI
Una terapia con anticorpi ha ripristinato il corretto funzionamento del sistema immunitario di un paziente adulto con Long COVID severo dimostrandosi così efficace per il trattamento di questa condizione. Il…
Emoglobinuria parossistica notturna (EPN), approvato in Italia Crovalimab, nuovo anticorpo monoclonale di prima linea
Offrire nuove prospettive terapeutiche e migliorare l’esperienza di cura e la qualità della vita dei pazienti: sono questi i benefici che vuole offrire Crovalimab, il nuovo anticorpo monoclonale somministrabile sottocute…
Long-Term Study Suggests Walking Is Key to Managing Cancer-Related Fatigue #IG26 #ASCO
A new study found that regular physical activity, particularly walking, can significantly reduce cancer-related fatigue and improve quality of life in people with colorectal cancer, especially in the post-treatment setting.…
Could reducing inflammation help combat fatigue in people with early-stage breast cancer?
New research reveals that inflammatory responses may play a role in different types of fatigue experienced by many people with cancer. The findings are published by Wiley online in CANCER,…
Inflammatory bowel diseases may be detectable at birth
Across the Western world, the prevalence of these chronic and serious conditions, which have no cure, is rising. In Denmark alone, 50,000 people suffer from either Crohn’s disease or ulcerative…
New study highlights scale and impact of long COVID. The Lancet
In a new review paper, researchers from the Universities of Arizona, Oxford and Leeds analyzed dozens of previous studies into long COVID to examine the number and range of people…
NIH opens long COVID trials to evaluate treatments for autonomic nervous system dysfunction
Two phase 2 clinical trials to test the safety and effectiveness of three treatments for adults with autonomic nervous system dysfunction from long COVID have begun. The autonomic nervous system…